3 unchanged sentences
Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
−Removed: Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our "Certifying Officers"), the effectiveness of our disclosure controls and procedures at December 31, 2024, pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
+Added: Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our "Certifying Officers"), the effectiveness of our disclosure controls and procedures at December 31, 2025, pursuant to Rule 13a-15(b) under the Exchange Act.
Based upon that evaluation, our Certifying Officers concluded that, at December 31, 2025, our disclosure controls and procedures were effective at achieving their intended objective.
22 unchanged sentences
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and financial statement schedules listed in the Index at Item 15(a) and our report dated March 3, 2025 expressed an unqualified opinion thereon.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and financial statement schedules listed in the Index at Item 15 and our report dated February 27, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
16 unchanged sentences
New York, New York
−Removed: March 3, 2025
+Added: February 27, 2026
Other Information.
−Removed: During the year ended December 31, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated (including by modification) a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K of the Securities Act).
+Added: During the three-months ended December 31, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated (including by modification) a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K of the Securities Act).
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
51 unchanged sentences
10-Q 001-39252 10.2 08/08/2022
−Removed: Employment Agreement, effect ive as of July 18, 2022, between the Registrant and Brady Priest
+Added: Employment Agreement, effective as of July 18, 2022, between the Registrant and Brady Priest
001-39252 10.14 03/01/2023
11 unchanged sentences
001-39252 10.17
−Removed: Insider Trad ing Policy
+Added: Insider Trading Policy
List of Subsidiaries
23 unchanged sentences
Clover Health Investments, Corp.
−Removed: March 3, 2025 By:
+Added: February 27, 2026 By:
/s/ Andrew Toy
3 unchanged sentences
/s/ Andrew Toy Chief Executive Officer (Principal Executive Officer) and Director Date:
−Removed: March 3, 2025
+Added: February 27, 2026
/s/ Peter Kuipers Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Date:
−Removed: March 3, 2025
+Added: February 27, 2026
Peter Kuipers
/s/ Vivek Garipalli Director and Executive Chair Date:
−Removed: March 3, 2025
+Added: February 27, 2026
Vivek Garipalli
−Removed: /s/ Chelsea Clinton Director Date:
−Removed: March 3, 2025
−Removed: Chelsea Clinton
/s/ Demetrios L.
Kouzoukas Director Date:
−Removed: March 3, 2025
−Removed: Shapiro Director Date:
−Removed: March 3, 2025
+Added: February 27, 2026
/s/ William G.
1 unchanged sentence
Director Date:
−Removed: March 3, 2025
+Added: February 27, 2026
Robinson, Jr.
1 unchanged sentence
Edwards Director Date:
−Removed: March 3, 2025
+Added: February 27, 2026
Carladenise A.
−Removed: Loengard Director Date:
−Removed: March 3, 2025
+Added: Loengard, M.D.
+Added: Director Date:
+Added: February 27, 2026
+Added: Loengard, M.D.
/s/ Thomas L.
Director Date:
−Removed: March 3, 2025
+Added: February 27, 2026
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.